Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

NCT04617522 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04617522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04617522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Recruiting
Start date
April 6, 2021
Completion date
December 31, 2026
Enrollment
30 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumor, liver failure